Chr Hansen & Nestlé settle on the patent dispute

Human Milk Oligosaccharides patent infringements
Chr Hansen & Nestlé settle on the patent dispute
Photo - Chr Hansen

In October 2020, Chr Hansen acquired Jennewein Biotechnologie, including a strong patent portfolio relating to the production of Human Milk Oligosaccharides (HMOs) and several litigations related hereto.

Before the acquisition in January 2020, Jennewein requested an injunction at the courts of Mannheim, Germany, against Nestlé’s sale of its infant formula products containing HMOs from a third party supplier that Jennewein believed and still believes is infringing several of Jennewein’s patents rights. In the opinion of Jennewein, Nestlé therefore also infringed these patent rights by selling infant formula products containing these HMOs.

As of May 11, 2021, Chr Hansen and Nestle have agreed to settle the patent dispute, including Chr. Hansen withdrawing the ongoing litigation in Mannheim, Germany, and Nestlé withdrawing the pending oppositions against the disputed patent rights. It has been agreed between the two companies not to disclose any further details of the settlement agreement.

Chr Hansen intends to maintain and expand the acquired portfolio of intellectual property rights covering HMOs and the production hereof and will keep enforcing such IP rights.

Chr Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. Chr Hansen is uniquely positioned to drive positive change through microbial solutions. It has worked for over 145 years to enable sustainable agriculture, cleaner labels, and healthier living for more people worldwide. The company’s microbial and fermentation technology platforms, including its broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends Chr Hansen continues to unlock the power of good bacteria to respond to global challenges such as food waste, global health, and the overuse of antibiotics and pesticides. As the world’s most sustainable biotech company, it touches the lives of more than 1 billion people every day.

No stories found.